SYNAIRGEN PLC

Regulatory Filings • May 8, 2025

National Storage Mechanism | Additional information

RNS Number : 8802H

Synairgen PLC

08 May 2025

 

Synairgen

('Synairgen' or the 'Company')

Shares Admitted to Trading on Asset Match

 

Southampton, UK - 8 May 2025: Synairgen, the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces the admission of its Ordinary Shares to trading on Asset Match ahead of its first auction.

Asset Match operates an electronic off-market dealing facility, which will allow existing Shareholders and new investors to trade Ordinary Shares by matching buyers and sellers through periodic auctions.

It is intended that the first auction in the Company's shares will be held in September 2025. Thereafter, auctions are expected to be held twice a year. More information, including exact auction dates and details on how to buy and sell, are available on the Company's website and Asset Match's company profile page .

Shareholders should contact Asset Match in relation to any queries regarding trading by emailing [email protected] .

Joseph Colliver, CFO of Synairgen, commented: "The Board is pleased to be working with Asset Match to provide ongoing liquidity for our shareholders and a platform for trading shares. We believe that the trading platform offers the capabilities to enable a simple continuation of trading of our shares as a private company."

Ben Weaver, Business Development Director of Asset Match, commented : "We're delighted to welcome Synairgen on-board the Asset Match platform. We're very pleased to be able to offer periodic liquidity in the Ordinary Shares for the shareholders who retained their holdings after the delisting from AIM, as the Company continues the development of SNG001 as a private company."

For further enquiries, please contact:

Synairgen plc	+ 44 (0)23 8051 2800
[email protected]

Notes for Editors

About Synairgen

Synairgen is a UK-based respiratory company focused on the development of SNG001 (inhaled interferon beta) as potentially the first broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.

Millions of people globally are hospitalised every year due to viral lung infections and there are currently no approved antiviral therapies for the majority of these patients. Synairgen is developing SNG001 to address this need.

For more information about Synairgen, please see www.synairgen.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFIFSTESITIIE